Serious Event

Serious Event

Serious Adverse Events (SAEs) are adverse events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability/incapacity, or are congenital anomalies/birth defects. Each serious event is categorized by term, organ system, assessment type, and source vocabulary to provide standardized reporting across clinical trials.

Serious Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Serious Event

Study -> Results Section -> Adverse Events Module -> Serious Event -> Serious Event Stats

Serious Event


Ignite Creation Date: 2025-12-24 @ 10:01 PM
Ignite Modification Date: 2025-12-25 @ 7:38 PM
NCT ID: NCT02758132
Term: intracranial hemorrhage
Organ System: Nervous system disorders
Assessment Type: NON_SYSTEMATIC_ASSESSMENT
Source Vocabulary: CTCAE 4.0
Notes: subject was admitted to the hospital on 9/3/2016. Subject had a significant history of CVA (stroke) with atrial fibrillation. Patient elected hospice and care expired on 9/8/2016. The event was a grade 5 and deemed unrelated to study treatment.
Study: NCT02758132
Study Brief: Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
Serious Event Stats (If Any):

Serious Event Stats

Group ID # Events # Affected # At Risk View
EG000 0 0 0 View
EG001 1 1 1 View